Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980249 | 0.92 | GRM6 (0.73) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL3974186 | 0.90 | GRM6 (0.61) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL3975104 | 0.89 | GRM6 (0.60) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL3974612 | 0.88 | GRM6 (0.61) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL4087642 | 0.87 | GRM6 (0.57) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL3981712 | 0.85 | GRM6 (0.57) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL4078131 | 0.82 | ADORA1 (0.68) | GRM6MAPTMEN1KMT2AMDM2 | |
| SCHEMBL25758961 | 0.76 | GRM6 (0.76) | GRM6MAPTMEN1KMT2APOLB | |
| SCHEMBL4090650 | 0.74 | ADORA1 (0.77) | GRM6MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4076833 | 0.74 | ADORA1 (0.66) | GRM6MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2009049362-A1 | A1 ADENOSINE RECEPTOR ALLOSTERIC ENHANCERS | MONASH UNIVERSITY (AU) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | GRM6 138/4885MAPT 4054/4885MEN1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.